Recent advances in dermatomyositis-specific autoantibodies
- 1 November 2016
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Rheumatology
- Vol. 28 (6), 636-644
- https://doi.org/10.1097/bor.0000000000000329
Abstract
In dermatomyositis, disease-specific autoantibodies now cover more than 70% of patients. These autoantibodies closely correlate with distinct clinical manifestations. In the past few years, extensive evidence has been accumulated on clinical significance of dermatomyositis-specific autoantibodies including autoantibodies against melanoma differentiation antigen 5 (MDA5), transcriptional intermediary factor 1 (TIF1), nuclear matrix protein 2 (NXP2), and small ubiquitin-like modifier activating enzyme (SAE). Anti-MDA5 antibodies are found with high specificity in clinically amyopathic dermatomyositis presenting rapidly progressive interstitial lung disease (ILD) especially in Asian population. Similar tendency has been reported in the US/Europe, although the frequency of positivity and the type of ILD may differ. Anti-TIF1 antibodies are present in juvenile and adult dermatomyositis patients with close correlation with malignancy in adult population. Anti-NXP2 antibodies share similar phenotype with anti-TIF1 antibodies, except that anti-NXP2 antibodies are associated with calcinosis and severe muscle disease. Although numbers are still small, patients with anti-SAE antibodies tend to present skin disease first and then progress to muscle weakness with systematic symptoms including dysphagia. Moreover, distinct cutaneous manifestations and muscle histopathology findings for each autoantibody have been reported. ‘Autoantibody-based classification’ of dermatomyositis subsets is now a useful strategy for comprehending the heterogeneous spectrum of dermatomyositis.Keywords
This publication has 47 references indexed in Scilit:
- Factors Associated with Interstitial Lung Disease in Patients with Polymyositis and Dermatomyositis: A Systematic Review and Meta-AnalysisPLOS ONE, 2016
- Myositis‐specific autoantibodies: an important tool to support diagnosis of myositisJournal of Internal Medicine, 2015
- Distinct profiles of myositis-specific autoantibodies in Chinese and Japanese patients with polymyositis/dermatomyositisClinical Rheumatology, 2015
- The Evolving Spectrum of Polymyositis and Dermatomyositis—Moving Towards Clinicoserological Syndromes: A Critical ReviewClinical Reviews in Allergy & Immunology, 2013
- Utility of Anti–Melanoma Differentiation–Associated Gene 5 Antibody Measurement in Identifying Patients With Dermatomyositis and a High Risk for Developing Rapidly Progressive Interstitial Lung Disease: A Review of the Literature and a Meta‐AnalysisArthritis Care & Research, 2013
- Dermatomyositis: Myositis‐specific autoantibodies and skin manifestationsClinical and Experimental Neuroimmunology, 2012
- The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): A retrospective studyJournal of the American Academy of Dermatology, 2011
- The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibodyRheumatology, 2009
- RNA helicase encoded by melanoma differentiation–associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung diseaseArthritis & Rheumatism, 2009
- Autoantibodies to a 140‐kd polypeptide, CADM‐140, in Japanese patients with clinically amyopathic dermatomyositisArthritis & Rheumatism, 2005